## JAZZ: Jazz Pharmaceuticals plc - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 8.5% in mid entry zone (4.0-10.0%), top 2% cross-sectional ranking. Caution: MRS_5 (-3.5%) diverging from MRS_20, watch for reversal. Outperforming sector by 7.1%. Caution: momentum weakening (-14.2% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($159.84)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Piper Sandler | $219 | $147 | +49% |
| 2025-11-24 | UBS | $188 | $163 | +15% |
| 2025-11-18 | Wells Fargo | $235 | $170 | +38% |
| 2025-11-18 | Baird | $209 | $160 | +31% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-11-24 | UBS | down | Neutral |
| 2025-11-18 | Wells Fargo | main | Overweight |
| 2025-11-18 | Baird | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.71M) |
| Sells | 10 ($6.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 9.7% (-3.0%)
- Blackrock Inc.: 9.2% (-4.2%)
- JPMORGAN CHASE & CO: 6.2% (+117.0%)
- Dimensional Fund Adv: 4.7% (+11.8%)
- Capital World Invest: 4.2% (+0.4%)

### Key Risks

1. Insider selling cluster: $6.4M in recent transactions.
2. Valuation stretched: PEG 4.0x requires aggressive growth execution.
3. Elevated short interest (9.2%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 6 raises (avg +25%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.97 signals overvaluation risk, limited margin of safety. Forward P/E 7.6x attractive for 180% earnings growth. Analyst sentiment positive (6 raises, avg +25%). Insider selling cluster ($6.4M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 0.31 |
| 52W Range | $95.49 - $182.99 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.97 |
| Forward P/E | 7.6 |
| Current P/E | 21.2 |
| YoY Growth | 180.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 22.7% to 8.5% (-14.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 97th percentile. MRS_5 (-3.5%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 9.8% shows strong absolute momentum above own 20MA. Outperforming sector by 7.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.46), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.50% (CS: 98) | Strong |
| RSI_14 | 66.9 | Neutral |
| MACD Histogram | 1.46 | Bullish |
| vs SMA20 | 1.098x | Above |
| vs SMA50 | 1.197x | Above |
| vs SMA200 | 1.380x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $172.12
- **Stop Loss:** $159.84 (7.1% risk)
- **Target:** $190.54 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $10,499.32
- **Portfolio %:** 10.50%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-24 (Est: $6.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.85 | $8.13 | +39.0% |
| 2025Q2 | $-6.25 | $-8.25 | -32.1% |
| 2025Q1 | $4.66 | $1.68 | -63.9% |
| 2024Q4 | $5.81 | $6.60 | +13.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*